{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T20:00:46Z","timestamp":1783972846612,"version":"3.55.0"},"reference-count":55,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2023,6,26]],"date-time":"2023-06-26T00:00:00Z","timestamp":1687737600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,6,26]],"date-time":"2023-06-26T00:00:00Z","timestamp":1687737600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Schmerz"],"published-print":{"date-parts":[[2023,8]]},"DOI":"10.1007\/s00482-023-00730-9","type":"journal-article","created":{"date-parts":[[2023,6,26]],"date-time":"2023-06-26T20:18:56Z","timestamp":1687810736000},"page":"297-307","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Klinische Anwendung von Botulinumtoxin Typ\u00a0A in der Schmerzmedizin","Clinical use of botulinum toxin type\u00a0A in pain medicine"],"prefix":"10.1007","volume":"37","author":[{"given":"A.","family":"Schwarzer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"M\u00e4cken","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E. K.","family":"Enax-Krumova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,6,26]]},"reference":[{"key":"730_CR1","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1007\/s00482-003-0203-4","volume":"17","author":"H G\u00f6bel","year":"2003","unstructured":"G\u00f6bel\u00a0H, Jost\u00a0WH, Arbeitsgruppe Schmerz im Arbeitskreis Botulinumtoxin der Deutschen Gesellschaft f\u00fcr Neurologie (2003) Botulinum-Toxin in der speziellen Schmerztherapie. Schmerz 17:149\u2013165","journal-title":"Schmerz"},{"key":"730_CR2","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1007\/s00482-003-0286-y","volume":"18","author":"R Placzek","year":"2004","unstructured":"Placzek\u00a0R, S\u00f6hling\u00a0M, Gessler\u00a0M, Jerosch\u00a0J (2004) Botulinumtoxin A in der orthop\u00e4dischen Schmerztherapie. Schmerz 18:498\u2013505","journal-title":"Schmerz"},{"issue":"6","key":"730_CR3","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1002\/ejp.1969","volume":"26","author":"J Slawek","year":"2022","unstructured":"Slawek\u00a0J (2022) Botulinum toxin A brands are not the same medications. A comment on Hary et\u00a0al. Eur J Pain 26(6):1396","journal-title":"Eur J Pain"},{"issue":"1","key":"730_CR4","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1007\/s42451-020-00271-w","volume":"4","author":"J Heckelmann","year":"2021","unstructured":"Heckelmann\u00a0J, Tapias\u00a0D, Dafotakis\u00a0M (2021) Botulinumtoxin in der Neurologie. DGNeurologie 4(1):12\u201315. https:\/\/doi.org\/10.1007\/s42451-020-00271-w","journal-title":"DGNeurologie"},{"issue":"2","key":"730_CR5","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1124\/pr.116.012658","volume":"69","author":"M Pirazzini","year":"2017","unstructured":"Pirazzini\u00a0M, Rossetto\u00a0O, Eleopra\u00a0R, Montecucco\u00a0C (2017) Botulinum neurotoxins: biology, pharmacology, and toxicology. Pharmacol Rev 69(2):200\u2013235","journal-title":"Pharmacol Rev"},{"key":"730_CR6","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1055\/s-0038-1627027","volume":"36","author":"C Sommer","year":"2017","unstructured":"Sommer\u00a0C, \u00dcceyler\u00a0N (2017) Botulinumtoxin zur Behandlung von neuropathischen Schmerzen. Nervenheilkunde 36:315\u2013323","journal-title":"Nervenheilkunde"},{"key":"730_CR7","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.pain.2003.10.008","volume":"107","author":"M Cui","year":"2004","unstructured":"Cui\u00a0M, Khanijou\u00a0S, Rubino\u00a0J, Aoki\u00a0KR (2004) Subcutaneous administration of botulinumtoxin A reduces formalin-induced pain. Pain 107:125\u2013133","journal-title":"Pain"},{"key":"730_CR8","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.neuroscience.2017.06.040","volume":"358","author":"I Matak","year":"2017","unstructured":"Matak\u00a0I, Tekus\u00a0V, B\u00f6lcskei\u00a0K, Lackovic\u00a0Z, Helyes\u00a0Z (2017) Involvement of substance P in the antinociceptive effect of botulinum toxin type A: Evidence from knockout mice. Neuroscience 358:137\u2013145","journal-title":"Neuroscience"},{"key":"730_CR9","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.pneurobio.2014.06.001","volume":"119\u2013120","author":"I Matak","year":"2014","unstructured":"Matak\u00a0I, Lackovic\u00a0Z (2014) Botulinum toxin A, brain and pain. Prog Neurobiol 119\u2013120:39\u201359","journal-title":"Prog Neurobiol"},{"issue":"2","key":"730_CR10","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.pbb.2009.08.012","volume":"94","author":"L Bach-Rojecky","year":"2009","unstructured":"Bach-Rojecky\u00a0L, Lackovi\u0107\u00a0Z (2009) Central origin of the antinociceptive action of botulinum toxin A. Pharmacol Biochem Behav 94(2):234\u2013238","journal-title":"Pharmacol Biochem Behav"},{"key":"730_CR11","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.ejphar.2010.01.020","volume":"633","author":"L Bach-Rojecky","year":"2010","unstructured":"Bach-Rojecky\u00a0L, Salkovic-Petrisic\u00a0M, Lackovic\u00a0Z (2010) Botulinum toxin type A reduces pain supersensitivity in experimental diabetic neuropathy: bilateral effect after unilateral injection. Eur J Pharmacol 633:10\u201314","journal-title":"Eur J Pharmacol"},{"key":"730_CR12","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.neuroscience.2011.04.026","volume":"186","author":"I Matak","year":"2011","unstructured":"Matak\u00a0I, Bach-Rojecky\u00a0L, Filipovi\u0107\u00a0B, Lackovi\u0107\u00a0Z (2011) Behavioral an immunohistochemical evidence for central antinociceptive activity of botulinum toxin A. Neuroscience 186:201\u2013207","journal-title":"Neuroscience"},{"issue":"1","key":"730_CR13","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1111\/bph.14846","volume":"177","author":"I Matak","year":"2020","unstructured":"Matak\u00a0I (2020) Evidence for central antispastic effect of botulinum toxin type A. Br J Pharmacol 177(1):65\u201376","journal-title":"Br J Pharmacol"},{"issue":"8","key":"730_CR14","doi-asserted-by":"crossref","first-page":"459","DOI":"10.3390\/toxins11080459","volume":"11","author":"I Matak","year":"2019","unstructured":"Matak\u00a0I, B\u00f6lcskei\u00a0K, Bach-Rojecky\u00a0L, Helyes\u00a0Z (2019) Mechanisms of botulinum toxin A action on pain. Toxins (Basel) 11(8):459","journal-title":"Toxins (Basel)"},{"key":"730_CR15","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/S1474-4422(16)00017-X","volume":"15","author":"N Attal","year":"2016","unstructured":"Attal\u00a0N, de Andrade\u00a0DC, Adam\u00a0F, Ranoux\u00a0D, Teixeira\u00a0MJ, Galhardoni\u00a0R, Raicher\u00a0I, \u00dcceyler\u00a0N, Sommer\u00a0C, Bouhassira\u00a0D (2016) Safety and efficacy of repeated injections of botulinum toxin A in peripheral neuropathic pain (BOTNEP): a\u00a0randomized, double-blind, placebo-controlled trial. Lancet Neurol 15:555\u2013565","journal-title":"Lancet Neurol"},{"issue":"5","key":"730_CR16","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1007\/s00482-017-0235-9","volume":"31","author":"L Eitner","year":"2017","unstructured":"Eitner\u00a0L, Vollert\u00a0J, Maier\u00a0C, Attal\u00a0N (2017) Botulinumtoxin\u2011A Injektion bei neuropathischem Schmerz. Schmerz 31(5):524\u2013526","journal-title":"Schmerz"},{"issue":"4","key":"730_CR17","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1002\/ana.24122","volume":"75","author":"K Paterson","year":"2014","unstructured":"Paterson\u00a0K, Lolignier\u00a0S, Wood\u00a0JN, McMahon\u00a0SB, Bennett\u00a0DL (2014) Botulinum Toxin\u2011A treatment reduces human mechanical pain sensitivity and mechanotransduction. Ann Neurol 75(4):591\u2013596","journal-title":"Ann Neurol"},{"key":"730_CR18","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1007\/s00115-020-00866-4","volume":"91","author":"W Hermann","year":"2020","unstructured":"Hermann\u00a0W (2020) Das Piriformissyndrom \u2013 eine spezielle Indikation f\u00fcr Botulinumtoxin. Nervenarzt 91:99\u2013106","journal-title":"Nervenarzt"},{"key":"730_CR19","doi-asserted-by":"crossref","first-page":"101951","DOI":"10.1016\/j.jcot.2022.101951","volume":"31","author":"MM Koh","year":"2022","unstructured":"Koh\u00a0MM, Tan\u00a0YL (2022) Use of botulinum neurotoxin in the treatment of piriformis syndrome: A systematic review. J\u00a0Clin Orthop Trauma 31:101951","journal-title":"J Clin Orthop Trauma"},{"issue":"1","key":"730_CR20","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.jhsa.2020.07.009","volume":"46","author":"JE Gallegos","year":"2021","unstructured":"Gallegos\u00a0JE, Inglesby\u00a0DC, Young\u00a0ZT, Herrera\u00a0FA (2021) Botulinum toxin for the treatment of intractable Raynaud phenomenon. J\u00a0Hand Surg Am 46(1):54\u201359","journal-title":"J Hand Surg Am"},{"issue":"1","key":"730_CR21","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1097\/DSS.0000000000002397","volume":"47","author":"L Quintana Castanedo","year":"2021","unstructured":"Quintana Castanedo\u00a0L, Feito Rodr\u00edguez\u00a0M, Nieto Rodr\u00edguez\u00a0D, Maseda Pedrero\u00a0R, Chiloeches Fern\u00e1ndez\u00a0C, de Lucas Laguna\u00a0R (2021) Botulinum toxin A treatment for primary and secondary Raynaud\u2019s phenomenon in teenagers. Dermatol Surg 47(1):61\u201364","journal-title":"Dermatol Surg"},{"issue":"5","key":"730_CR22","first-page":"CD012551","volume":"5","author":"JV Franco","year":"2018","unstructured":"Franco\u00a0JV, Turk\u00a0T, Jung\u00a0JH, Xiao\u00a0YT, Iakhno\u00a0S, Garrote\u00a0V, Vietto\u00a0V (2018) Non-pharmacological interventions for treating chronic prostatitis\/chronic pelvic pain syndrome. Cochrane Database Syst Rev 5(5):CD12551","journal-title":"Cochrane Database Syst Rev"},{"issue":"1","key":"730_CR23","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/j.euf.2021.01.005","volume":"8","author":"BA Parsons","year":"2022","unstructured":"Parsons\u00a0BA, Goonewardene\u00a0S, Dabestani\u00a0S, Pacheco-Figueiredo\u00a0L, Yuan\u00a0Y, Zumstein\u00a0V, Cottrell\u00a0AM, Borovicka\u00a0J, Dinis-Oliveira\u00a0P, Berghmans\u00a0B, Elneil\u00a0S, Hughes\u00a0J, Messelink\u00a0BEJ, de Williams\u00a0AC, Baranowski\u00a0AP, Engeler\u00a0DS (2022) The benefits and harms of botulinum toxin\u2011A in the treatment of chronic pelvic pain syndromes: a systematic review by the European Association of Urology chronic pelvic pain panel. Eur Urol Focus 8(1):320\u2013338","journal-title":"Eur Urol Focus"},{"key":"730_CR24","volume-title":"Leitlinien f\u00fcr Diagnostik und Therapie in der Neurologie","author":"T Platz","year":"2018","unstructured":"Platz\u00a0T et al (2018) Therapie des spastischen Syndroms, S2k-Leitlinie. In: Deutsche Gesellschaft f\u00fcr Neurologie (Hrsg) Leitlinien f\u00fcr Diagnostik und Therapie in der Neurologie"},{"key":"730_CR25","volume-title":"Leitlinien f\u00fcr Diagnostik und Therapie in der Neurologie","author":"CW Ip","year":"2021","unstructured":"Ip\u00a0CW et al (2021) Dystonie, S1-Leitlinie. In: Deutsche Gesellschaft f\u00fcr Neurologie (Hrsg) Leitlinien f\u00fcr Diagnostik und Therapie in der Neurologie"},{"key":"730_CR26","unstructured":"Diener H\u2011C, F\u00f6rderreuther S, Kropp P et al (2022) Therapie der Migr\u00e4neattacke und Prophylaxe der Migr\u00e4ne, S1-Leitlinie, 2022, DGN und DMKG. In: Deutsche Gesellschaft f\u00fcr Neurologie (Hrsg) Leitlinien f\u00fcr Diagnostik und Therapie in der Neurologie. https:\/\/dnvp9c1uo2095.cloudfront.net\/cms-content\/030057_LL_Migra%CC%88ne_2022_1671539591923.pdf. Zugegriffen: 20.03.2023"},{"issue":"7","key":"730_CR27","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1177\/0333102410364676","volume":"30","author":"SK Aurora","year":"2010","unstructured":"Aurora\u00a0SK, Dodick\u00a0DW, Turkel\u00a0CC, DeGryse\u00a0RE, Silberstein\u00a0SD, Lipton\u00a0RB et al (2010) OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 1 trial. Cephalalgia 30(7):793\u2013803","journal-title":"Cephalalgia"},{"issue":"7","key":"730_CR28","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1177\/0333102410364677","volume":"30","author":"HC Diener","year":"2010","unstructured":"Diener\u00a0HC, Dodick\u00a0DW, Aurora\u00a0SK, Turkel\u00a0CC, DeGryse\u00a0RE, Lipton\u00a0RB et al (2010) OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 2 trial. Cephalalgia 30(7):804\u2013814","journal-title":"Cephalalgia"},{"issue":"1-2","key":"730_CR29","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.jns.2013.05.003","volume":"331","author":"SD Silberstein","year":"2013","unstructured":"Silberstein\u00a0SD, Blumenfeld\u00a0AM, Cady\u00a0RK, Turner\u00a0IM, Lipton\u00a0RB, Diener\u00a0HC et al (2013) OnabotulinumtoxinA for treatment of chronic migraine: PREEMPT 24-week pooled subgroup analysis of patients who had acute headache medication overuse at baseline. J\u00a0Neurol Sci 331(1-2):48\u201356","journal-title":"J Neurol Sci"},{"issue":"3","key":"730_CR30","doi-asserted-by":"crossref","first-page":"333102422115023","DOI":"10.1177\/03331024221150231","volume":"43","author":"CS Dhanasekara","year":"2023","unstructured":"Dhanasekara\u00a0CS, Payberah\u00a0D, Chyu\u00a0JY, Shen\u00a0CL, Kahathuduwa\u00a0CN (2023) The effectiveness of botulinum toxin for chronic tension-type headache prophylaxis: A systematic review and meta-analysis. Cephalalgia 43(3):3331024221150231","journal-title":"Cephalalgia"},{"issue":"6","key":"730_CR31","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1177\/0333102415597891","volume":"36","author":"DF Bratbak","year":"2016","unstructured":"Bratbak\u00a0DF, Nordg\u00e5rd\u00a0S, Stovner\u00a0LJ, Linde\u00a0M, Folvik\u00a0M, Bugten\u00a0V, Tronvik\u00a0E (2016) Pilot study of sphenopalatine injection of onabotulinumtoxinA for the treatment of intractable chronic cluster headache. Cephalalgia 36(6):503\u2013509","journal-title":"Cephalalgia"},{"issue":"8","key":"730_CR32","doi-asserted-by":"crossref","first-page":"1632","DOI":"10.1111\/head.13889","volume":"60","author":"J Crespi","year":"2020","unstructured":"Crespi\u00a0J, Bratbak\u00a0D, Dodick\u00a0DW, Matharu\u00a0M, Solheim\u00a0O, Gulati\u00a0S, Berntsen\u00a0EM, Tronvik\u00a0E (2020) Open-label, multi-dose, pilot safety study of injection of OnabotulinumtoxinA toward the otic ganglion for the treatment of intractable chronic cluster headache. Headache 60(8):1632\u20131643","journal-title":"Headache"},{"issue":"5-6","key":"730_CR33","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1093\/milmed\/usaa391","volume":"186","author":"MD Zirovich","year":"2021","unstructured":"Zirovich\u00a0MD, Pangarkar\u00a0SS, Manh\u00a0C, Chen\u00a0L, Vangala\u00a0S, Elashoff\u00a0DA, Izuchukwu\u00a0IS (2021) Botulinum toxin type A for the treatment of post-traumatic headache: a randomized, placebo-controlled, cross-over study. Mil Med 186(5-6):493\u2013499","journal-title":"Mil Med"},{"issue":"2","key":"730_CR34","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/S1474-4422(14)70251-0","volume":"14","author":"NB Finnerup","year":"2015","unstructured":"Finnerup\u00a0NB, Attal\u00a0N, Haroutounian\u00a0S, McNicol\u00a0E, Baron\u00a0R, Dworkin\u00a0RH, Gilron\u00a0I, Haanp\u00e4\u00e4\u00a0M, Hansson\u00a0P, Jensen\u00a0TS, Kamerman\u00a0PR, Lund\u00a0K, Moore\u00a0A, Raja\u00a0SN, Rice\u00a0AS, Rowbotham\u00a0M, Sena\u00a0E, Siddall\u00a0P, Smith\u00a0BH, Wallace\u00a0M (2015) Pharmacotherapy for neuropathic painin adults: a systematic review an metaanalysis. Lancet Neurol 14(2):162\u2013173","journal-title":"Lancet Neurol"},{"issue":"5","key":"730_CR35","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1097\/WCO.0000000000000980","volume":"34","author":"N Attal","year":"2021","unstructured":"Attal\u00a0N, Bouhassira\u00a0D (2021) Advances in the treatment of neuropathic pain. Curr Opin Neurol 34(5):631\u2013637","journal-title":"Curr Opin Neurol"},{"key":"730_CR36","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.neurol.2018.08.005","volume":"175","author":"N Attal","year":"2019","unstructured":"Attal\u00a0N (2019) Pharmacological treatments of neuropathic pain: The latest recommendations. Rev Neurol 175:46\u201350","journal-title":"Rev Neurol"},{"issue":"1","key":"730_CR37","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1186\/s10194-017-0744-z","volume":"18","author":"G Sandrini","year":"2017","unstructured":"Sandrini\u00a0G, De Icco\u00a0R, Tassorelli\u00a0C, Smania\u00a0N, Tamburin\u00a0S (2017) Botulinum neurotoxin type A for the treatment of pain: not just in migraine and trigeminal neuralgia. J\u00a0Headache Pain 18(1):38","journal-title":"J Headache Pain"},{"key":"730_CR38","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.toxicon.2018.01.017","volume":"147","author":"Y Safarpour","year":"2018","unstructured":"Safarpour\u00a0Y, Jabbari\u00a0B (2018) Botulinum toxin treatment of pain syndromes\u2014an evidence based review. Toxicon 147:120\u2013128","journal-title":"Toxicon"},{"issue":"2","key":"730_CR39","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/s42466-020-00063-3","volume":"10","author":"T Schlereth","year":"2020","unstructured":"Schlereth\u00a0T (2020) Guideline \u201cdiagnosis and non interventional therapy of neuropathic pain\u201d of the German Society of Neurology (deutsche Gesellschaft f\u00fcr Neurologie). Neurol Res 10(2):16. https:\/\/doi.org\/10.1186\/s42466-020-00063-3","journal-title":"Neurol Res"},{"key":"730_CR40","doi-asserted-by":"crossref","first-page":"716","DOI":"10.3389\/fneur.2020.00716","volume":"11","author":"G Egeo","year":"2020","unstructured":"Egeo\u00a0G, Fofi\u00a0L, Barbanti\u00a0P (2020) Botulinum neurotoxin for the treatment of neuropathic pain. Front Neurol 11:716","journal-title":"Front Neurol"},{"issue":"10","key":"730_CR41","doi-asserted-by":"crossref","first-page":"e01409","DOI":"10.1002\/brb3.1409","volume":"9","author":"J Wei","year":"2019","unstructured":"Wei\u00a0J, Zhu\u00a0X, Yang\u00a0G, Shen\u00a0J, Xie\u00a0P, Zuo\u00a0X, Xia\u00a0L, Han\u00a0Q, Zhao\u00a0V (2019) The efficacy and safety of botulinum toxin type A in treatment of trigeminal neuralgia and peripheral neuropathic pain: A meta-analysis of randomized controlled trials. Brain Behav 9(10):e1409","journal-title":"Brain Behav"},{"issue":"8","key":"730_CR42","doi-asserted-by":"crossref","first-page":"758","DOI":"10.3390\/jpm11080758","volume":"11","author":"S Ri","year":"2021","unstructured":"Ri\u00a0S, Kivi\u00a0A, Wissel\u00a0J (2021) The safety and effect of local Botulinumtoxin A injections for long-term management of chronic pain in post-herpetic neuralgia: Literature review and cases report treated with Incobotulinumtoxin A. J\u00a0Pers Med 11(8):758","journal-title":"J Pers Med"},{"key":"730_CR43","doi-asserted-by":"crossref","first-page":"3855","DOI":"10.2147\/JPR.S340390","volume":"14","author":"C Wang","year":"2021","unstructured":"Wang\u00a0C, Zhang\u00a0Q, Wang\u00a0R, Xu\u00a0L (2021) Botulinum toxin type A for diabetic peripheral neuropathy pain: a systematic review and meta-analysis. J\u00a0Pain Res 14:3855\u20133863","journal-title":"J Pain Res"},{"issue":"3","key":"730_CR44","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1002\/ana.21427","volume":"64","author":"D Ranoux","year":"2008","unstructured":"Ranoux\u00a0D, Attal\u00a0N, Morain\u00a0F, Bouhassira\u00a0D (2008) Botulinum toxin type A induces direct analgesic effects in chronic neuropathic pain. Ann Neurol 64(3):274\u2013283","journal-title":"Ann Neurol"},{"issue":"4","key":"730_CR45","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1097\/j.pain.0000000000002130","volume":"162","author":"D Bouhassira","year":"2021","unstructured":"Bouhassira\u00a0D, Branders\u00a0S, Attal\u00a0N, Fernandes\u00a0AM, Demolle\u00a0D, Barbour\u00a0J, Ciampi de Andrade\u00a0D, Pereira\u00a0A (2021) Stratification of patients based on the Neuropathic Pain Symptom Inventory: development and validation of a\u00a0new algorithm. Pain 162(4):1038\u20131046","journal-title":"Pain"},{"issue":"1","key":"730_CR46","doi-asserted-by":"crossref","first-page":"36","DOI":"10.3390\/toxins14010036","volume":"14","author":"A Datta Gupta","year":"2022","unstructured":"Datta Gupta\u00a0A, Edwards\u00a0S, Smith\u00a0J, Snow\u00a0J, Visvanathan\u00a0R, Tucker\u00a0G, Wilson\u00a0D (2022) A systematic review and meta-analysis of efficacy of Botulinum toxin A foe neuropathic pain. Toxins (Basel) 14(1):36","journal-title":"Toxins (Basel)"},{"key":"730_CR47","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1002\/ejp.1941","volume":"26","author":"V Hary","year":"2022","unstructured":"Hary\u00a0V, Schitter\u00a0S, Martinez\u00a0V (2022) Efficacy and safety of botulinum A toxin for the treatment of chronic peripheral neuropathic pain: A systematic review of randomized controlled trials an meta-analysis. Eur J Pain 26:980\u2013990","journal-title":"Eur J Pain"},{"issue":"1","key":"730_CR48","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/s00482-019-00416-1","volume":"34","author":"M Kaisler","year":"2020","unstructured":"Kaisler\u00a0M, Maier\u00a0C, Kumowski\u00a0N, Schwarzer\u00a0A, Meyer-Frie\u00dfem\u00a0CH (2020) Langzeiteffektivit\u00e4t topischer applizierter Analgetika. Schmerz 34(1):21\u201332","journal-title":"Schmerz"},{"issue":"10","key":"730_CR49","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1080\/03007995.2019.1626228","volume":"35","author":"CH Meyer-Frie\u00dfem","year":"2019","unstructured":"Meyer-Frie\u00dfem\u00a0CH, Eitner\u00a0LB, Kaisler\u00a0M, Maier\u00a0C, Vollert\u00a0J, Westermann\u00a0A, Zahn\u00a0PK, Avila Gonzalez\u00a0CA (2019) Perineural injection of Botulinum toxin\u2011A in painful peripheral nerve injury\u2014a\u00a0case-series: pain relief, safety, sensory profile, an sample size recommendation. Curr Med Res Opin 35(10):1793\u20131803","journal-title":"Curr Med Res Opin"},{"issue":"7","key":"730_CR50","first-page":"CD004598","volume":"7","author":"NE O\u2019Connell","year":"2016","unstructured":"O\u2019Connell\u00a0NE, Wand\u00a0BM, Gibson\u00a0W, Carr\u00a0DB, Birklein\u00a0F, Stanton\u00a0TR (2016) Local anaesthetic sympathetic blockade for complex regional pain syndrome. Cochrane Database Syst Rev 7(7):CD4598","journal-title":"Cochrane Database Syst Rev"},{"issue":"6","key":"730_CR51","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1097\/AAP.0b013e318229bbee","volume":"36","author":"EK Krumova","year":"2011","unstructured":"Krumova\u00a0EK, Gussone\u00a0C, Regeniter\u00a0S, Westermann\u00a0A, Zenz\u00a0M, Maier\u00a0C (2011) Are sympathetic blocks useful for diagnostic purposes? Reg Anesth Pain Med 36(6):560\u2013567","journal-title":"Reg Anesth Pain Med"},{"issue":"3","key":"730_CR52","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1002\/ana.21601","volume":"65","author":"I Carroll","year":"2009","unstructured":"Carroll\u00a0I, Clark\u00a0JD, Mackey\u00a0S (2009) Sympathetic block with botulinum toxin to treat complex regional pain syndrome. Ann Neurol 65(3):348\u2013351","journal-title":"Ann Neurol"},{"issue":"2","key":"730_CR53","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1097\/ALN.0000000000004084","volume":"136","author":"Y Yoo","year":"2022","unstructured":"Yoo\u00a0Y, Lee\u00a0CS, Kim\u00a0J, Jo\u00a0D, Moon\u00a0JY (2022) Botulinum toxin type A for lumbar sympathetic ganglion block in complex regional pain syndrome: a randomized trial. Anesthesiology 136(2):314\u2013325","journal-title":"Anesthesiology"},{"issue":"2","key":"730_CR54","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1097\/ALN.0000000000004093","volume":"136","author":"V Singh","year":"2022","unstructured":"Singh\u00a0V, Cohen\u00a0SP (2022) Prolonging sympathetic blockade for complex regional pain syndrome: is Botulinum toxin the answer? Anesthesiology 136(2):261\u2013264","journal-title":"Anesthesiology"},{"issue":"5","key":"730_CR55","doi-asserted-by":"crossref","first-page":"308","DOI":"10.3390\/toxins14050308","volume":"14","author":"L Lippi","year":"2022","unstructured":"Lippi\u00a0L, de Sire\u00a0A, Folli\u00a0A, D\u2019Abrosca\u00a0F, Grana\u00a0E, Baricich\u00a0A, Carda\u00a0S, Invernizzi\u00a0M (2022) Multidimensional effectiveness of botulinum toxin in neuropathic pain: a systematic review of randomized clinical trials. Toxins (Basel) 14(5):308","journal-title":"Toxins (Basel)"}],"container-title":["Der Schmerz"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00482-023-00730-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00482-023-00730-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00482-023-00730-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,15]],"date-time":"2023-12-15T21:04:47Z","timestamp":1702674287000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00482-023-00730-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,26]]},"references-count":55,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,8]]}},"alternative-id":["730"],"URL":"https:\/\/doi.org\/10.1007\/s00482-023-00730-9","relation":{},"ISSN":["0932-433X","1432-2129"],"issn-type":[{"value":"0932-433X","type":"print"},{"value":"1432-2129","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,26]]},"assertion":[{"value":"3 April 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 April 2023","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 April 2023","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 June 2023","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"Gem\u00e4\u00df den Richtlinien des Springer Medizin Verlags werden Autoren und Wissenschaftliche Leitung im Rahmen der Manuskripterstellung und Manuskriptfreigabe aufgefordert, eine vollst\u00e4ndige Erkl\u00e4rung zu ihren finanziellen und nichtfinanziellen Interessen abzugeben.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"<b>A. Schwarzer<\/b>: A. Finanzielle Interessen: A. Schwarzer gibt an, dass kein finanzieller Interessenkonflikt besteht.\u00a0\u2013 B. Nichtfinanzielle Interessen: Angestellter leitender Arzt (komm.) der Abteilung f\u00fcr Schmerzmedizin, Berufsgenossenschaftliches Universit\u00e4tsklinikum gGmbH, B\u00fcrkle-de-la-Camp-Platz\u00a01, 44789 Bochum | Mitgliedschaft: Deutsche Schmerzgesellschaft (DGSS). <b>T. M\u00e4cken<\/b>: A. Finanzielle Interessen: Reise- und \u00dcbernachtungskosten f\u00fcr Vortragst\u00e4tigkeit auf Kongressen (Fa. Pajunk Medical Produkte). | Referentenhonorar \u00c4rztekammer Westfalen-Lippe (Workshop und Vortrag, Kurs Spezielle Schmerzmedizin).\u00a0 B. Nichtfinanzielle Interessen: Angestellter An\u00e4sthesist, Oberarzt der Klinik f\u00fcr An\u00e4sthesiologie, Intensiv- und Schmerzmedizin, Direktor: Prof. Dr. med. Peter K. Zahn, BG Universit\u00e4tsklinikum Bergmannsheil Bochum | Mitgliedschaften: Deutsche Gesellschaft f\u00fcr Ultraschall in der Medizin (DEGUM), European Society of Regional Anaesthesia and Pain Therapy (ESRA), Deutsche Gesellschaft f\u00fcr An\u00e4sthesiologie und Intensivmedizin (DGAI), DGSS, Gesch\u00e4ftsf\u00fchrer USRA Medical Education. <b>E. Enax-Krumova<\/b>: A. Finanzielle Interessen: Stiftungsprofessur der Deutschen Gesetzlichen Unfallversicherung (DGUV); Georgius Agricola Stiftung Ruhr\u00a0\u2013 projektbezogene F\u00f6rderung; Medizinische Fakult\u00e4t der Ruhr-Universit\u00e4t Bochum\u00a0\u2013 intramurale projektbezogene F\u00f6rderung; Bundesministerium f\u00fcr Wirtschaft und Technologie (BMWi)\u00a0\u2013 projektbezogene F\u00f6rderung im Rahmen eines Verbundvorhabens.\u00a0\u2013 Vortragshonorar: Novartis GmbH.\u00a0\u2013 Omega Pharma GmbH\u00a0\u2013 Treffen eines Advisory Board.\u00a0\u2013 B. Nichtfinanzielle Interessen: Angestellte Fach\u00e4rztin f\u00fcr Neurologie an der Neurologischen Klinik, BG Universit\u00e4tsklinikum Bergmannsheil gGmbH Bochum; Stiftungsprofessur (W1) f\u00fcr \u201eNeuronale Regenerationsforschung\u201c | Mitgliedschaften: Deutsche Gesellschaft f\u00fcr Neurologie e.\u202fV., Deutsche Schmerzgesellschaft e.\u202fV., International Association for the Study of Pain (IASP), IASP Neuropathic Pain Special Interest Group, IASP Complex Regional Pain Syndrom Special Interest Group, Deutsche Migr\u00e4ne- und Kopfschmerzgesellschaft (DMKG) e.\u202fV., Deutsche Gesellschaft f\u00fcr Klinische Neurophysiologie und Funktionelle Bildgebung (DGKN) e.\u202fV., Deutscher Forschungsverbund Neuropathischer Schmerz (DFNS) e.\u202fV., Gesellschaft f\u00fcr Medizinische Ausbildung (GMA) e.\u202fV., Deutscher \u00c4rztinnenbund e.\u202fV.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Autoren"}},{"value":"Die vollst\u00e4ndige Erkl\u00e4rung zum Interessenkonflikt der Wissenschaftlichen Leitung finden Sie am Kurs der zertifizierten Fortbildung auf.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Wissenschaftliche Leitung"}},{"value":"erkl\u00e4rt, dass f\u00fcr die Publikation dieser CME-Fortbildung keine Sponsorengelder an den Verlag flie\u00dfen.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Der Verlag"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autor\/-innen keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Der Verlag"}}]}}